Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2005

View Archived Issues

New data on the benefits of APC-8015 in prostate cancer

AZD-3409 inhibits proliferation and invasion in prostate epithelial cells

Isoliquiritigenin downregulates androgen-receptor and PSA proteins

MediciNova opens phase I study for MN-221

Phase I study of Acrux transdermal spray to prevent nausea in cancer patients

Repligen enters into development agreement for uridine for bipolar disorder

Efficacy of MIV-310 in phase II HIV trial does not warrant further development

Prana begins phase I trial for PBT-2

IND accepted for clinical testing of Moli-1901 for dry eye syndrome

FDA rejects Public Citizen's petition for Crestor

Phase II study of GCAN-101 set to begin in Israel

Shionogi & Co. initiate phase I Japanese studies for Enanta antibiotic

Dainippon obtains development and marketing rights for KGA-2727 in Japan

Acyl-CoA: cholesterol acyltransferase inhibition in the treatment of Alzheimer's disease

L-791515 shows efficacy as an analgesic for postoperative dental pain

TC-1827, a nicotinic acetylcholine receptor agonist improves cognitive function

Drug-drug interactions with clopidogrel and St. John's wort

Potent and selective mGluR5 antagonist shows good PK profile

Preclinical evidence for the cognitive-enhancing effects of ZSET-1446

New agents for antiinflammatory disorders described in patent literature

Lilly scientists report the discovery of novel tachykinin NK1 receptor antagonists

Oxytocin antagonists from GlaxoSmithKline reported in patent literature

Orion reports a novel series of SARMs

Temodar approved for newly diagnosed GBM

FDA places clinical hold on studies with alpha4 integrin antagonists

FDA approves Mycamine

Symlin receives FDA approval

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...